CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss Per Common Shares (Tables)

Loss Per Common Shares (Tables)

6 Months Ended

Nov. 30, 2022

Loss Per Common Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net loss per share


		Three months ended November 30,						Six months ended November 30,
(in thousands, except per share amounts)		2022			2021			2022			2021
						(Restated) ⁽¹⁾						(Restated) ⁽¹⁾
Net loss		$	(26,495)		$	(40,077)		$	(47,486)		$	(85,414)
Less: Deemed dividends			(1,140)			—			(5,294)			—
Less: Accrued preferred stock dividends			(370)			(417)			(756)			(842)
Net loss applicable to common stockholders		$	(28,005)		$	(40,494)		$	(53,536)		$	(86,256)
Basic and diluted:
Weighted average common shares outstanding			813,373			662,600			800,545			647,517
Loss per share		$	(0.03)		$	(0.06)		$	(0.07)		$	(0.13)

(1) See Note 2, Summary of Significant Accounting Policies.

Schedule of securities excluded from computation of earnings per share


	Three and six months ended November 30,
(in thousands)	2022		2021
Stock options, warrants, and unvested restricted stock units	204,273		73,223
Convertible notes	12,000		12,000
Convertible preferred stock	32,591		34,089